Project Grant R01DA065287
- The National Institute on Drug Abuse awarded the Regents of the University of Minnesota $423,500 under the Drug Use and Addiction Research Programs (CFDA 93.279) on April 1, 2026. The award funds research into the therapeutic potential of M5 receptor targeting in stress-induced potentiation of drug reward. The project investigates how stress exposure disrupts M5 receptor-mediated regulation of dopamine transmission in midbrain dopamine neurons, increasing vulnerability to substance use...
- The National Institute on Drug Abuse awarded the Regents of the University of Minnesota $673,724 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to study how opioid exposure modifies nucleus accumbens microcircuits and to develop strategies to reverse or prevent maladaptive opioid-evoked neural plasticity. The research focuses on low-threshold spiking interneurons (LTSIs) in the nucleus accumbens, which are gatekeepers of nucleus accumbens output and regulate...
- The National Institute on Drug Abuse awarded Carnegie Mellon University $217,672 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to measure how addiction-associated genetic variants regulate gene expression across specific brain regions in response to opioids and cocaine. The research measures regulatory activity of candidate human addiction-associated genetic enhancers in the striatum, cortex, hippocampus, and amygdala of mice using in vivo massively parallel...
- The National Institute on Drug Abuse awarded the University of California, San Diego $169,832 on September 30, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research into the genetic basis of addiction-related behaviors. The project uses long-read sequencing technology to discover and characterize tandem repeats and structural variants in the genomes of N/NIH Heterogeneous Stock rats, genetic variants that conventional genome-wide association studies overlook....
- The National Institute on Alcohol Abuse and Alcoholism awarded the Regents of the University of Minnesota $157,040 on March 9, 2026, under the Alcohol Research Programs (CFDA 93.273) project grant F32AA032727. The funded research investigates neural mechanisms driving compulsive alcohol drinking despite negative consequences, termed aversion-resistant alcohol drinking (ARD). Using optogenetics and simultaneous in-vivo electrophysiology in male and female Long-Evans rats, the project examines how...
- The National Institute on Drug Abuse awarded the University of Southern California $149,766 on August 12, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate simultaneous nicotine, alcohol, and cannabis co-use among young adults. The funded research examines patterns of use, subjective experiences, and consequences of simultaneous substance co-use—defined as using multiple substances close in time so their effects overlap—among approximately 3,860 young adults...
- The National Institute on Drug Abuse awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $1.266 million on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to establish and operate the NIDA Center of Excellence in Omics, Systems Genetics, and the Addictome. The center delivers training, data resources, and analytical tools enabling substance use disorder researchers to integrate data science, quantitative...
- The National Institute on Drug Abuse awarded The General Hospital Corporation (Massachusetts General Hospital) $769,268 under the Drug Use and Addiction Research Programs (CFDA 93.279) on March 1, 2026, for a project examining genomic tests for substance use disorders in clinical care. The project investigates the ethical, clinical, and policy implications of polygenic risk score (PRS) genetic tests for opioid use disorder (OUD) and other substance use disorders in medical practice. The research...
- The National Institute on Drug Abuse awarded the University of California, San Diego $879,000 on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate a novel episode-based paradigm for studying how family processes drive adolescent substance use. The project will collect real-time, real-world intensive longitudinal data on discrete parent and youth behaviors before and after episodes of substance use from 90 adolescents who use substances....
- The National Institute on Drug Abuse awarded New York University $103,607 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct dissertation research on polysubstance use patterns and their associations with methadone maintenance treatment receipt and discontinuation among people who use drugs in New York State. The research uses a mixed-methods approach guided by the Social Ecological Model to identify latent polysubstance use patterns through urine...
The National Institute on Drug Abuse awarded the Regents of the University of Minnesota $716,254 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a global network study of population, family, and longitudinal human genetic research on tobacco and alcohol use. The award funds research integrating 9 million individuals of global ancestries across a worldwide consortium to identify genetic loci associated with nicotine and alcohol use disorder. The study employs novel meta-analytic methods to leverage ancestral variation and recent ancestry admixture, increasing statistical power and refining effect size estimates within and across major ancestries. Among the 9 million participants, 650,000 are first-degree relatives whose familial relationships remove confounding effects such as population stratification, cryptic genetic relatedness, and familial environmental influences critical to understanding tobacco and alcohol use. The research advances etiological knowledge through genome-wide association studies (GWAS) addressing longstanding challenges in population-based genetic research, including population stratification and ascertainment bias, with particular attention to younger cohorts historically underrepresented in genetic studies of complex disease. Work is performed in Minneapolis, Minnesota. The period of performance runs from September 1, 2026, through June 30, 2031. The award is classified as a Project Grant supporting basic and translational research in substance use to develop prevention, diagnosis, and treatment approaches for drug use, misuse, addiction, and related health outcomes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $716.3k | 8/24/26 |